- Home
- CELC vs TECX Comparison
CELC vs TECX Comparison
Compare CELC & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- TECX
- Stock Information
- Founded
- CELC 2011
- TECX 2019
- Country
- CELC United States
- TECX United States
- Employees
- CELC N/A
- TECX N/A
- Industry
- CELC Medical Specialities
- TECX
- Sector
- CELC Health Care
- TECX
- Exchange
- CELC Nasdaq
- TECX Nasdaq
- Market Cap
- CELC 440.0M
- TECX 387.1M
- IPO Year
- CELC 2017
- TECX 2018
- Fundamental
- Price
- CELC $51.79
- TECX $23.51
- Analyst Decision
- CELC Strong Buy
- TECX Strong Buy
- Analyst Count
- CELC 6
- TECX 5
- Target Price
- CELC $46.50
- TECX $79.00
- AVG Volume (30 Days)
- CELC 2.9M
- TECX 230.2K
- Earning Date
- CELC 08-14-2025
- TECX 08-07-2025
- Dividend Yield
- CELC N/A
- TECX N/A
- EPS Growth
- CELC N/A
- TECX N/A
- EPS
- CELC N/A
- TECX N/A
- Revenue
- CELC N/A
- TECX N/A
- Revenue This Year
- CELC N/A
- TECX N/A
- Revenue Next Year
- CELC N/A
- TECX N/A
- P/E Ratio
- CELC N/A
- TECX N/A
- Revenue Growth
- CELC N/A
- TECX N/A
- 52 Week Low
- CELC $7.58
- TECX $13.70
- 52 Week High
- CELC $53.70
- TECX $61.07
- Technical
- Relative Strength Index (RSI)
- CELC 92.18
- TECX 56.50
- Support Level
- CELC $38.00
- TECX $21.31
- Resistance Level
- CELC $53.40
- TECX $23.12
- Average True Range (ATR)
- CELC 3.33
- TECX 1.53
- MACD
- CELC 0.92
- TECX 0.13
- Stochastic Oscillator
- CELC 89.44
- TECX 71.85
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.